Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells
Yong Huang(Institute of Infection and Immunity), Imre Noth(University of Virginia), Jose D. Herazo‐Maya(University of South Florida), Catherine A. Bonham(MACOM (United States)), Rekha Vij(University of Chicago), Bethany B. Moore(University of Michigan), Andrew Barros(University of Virginia), Toby M. Maher(University of Southern California), Philip L. Molyneaux(Guy's and St Thomas' NHS Foundation Trust), Ayodeji Adegunsoye(University of Chicago), Shwu‐Fan Ma(University of Chicago), Mary E. Strek(University of Chicago), Avraham Unterman(Tel Aviv University), Naftali Kaminski(Yale University), Fernando J. Martínez(University of Massachusetts Chan Medical School), John S. Kim(University of Virginia), Shu-Yi Liao(National Jewish Health), Justin M. Oldham(Michigan Medicine)
Cited by 54
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
|American Journal of Respiratory and Critical Care Medicine|2010|1k